Search for: "Apotex Corporation" Results 101 - 120 of 135
Sort by Relevance | Sort by Date
RSS Subscribe: 20 results | 100 results
26 Aug 2009, 6:12 am
The Corporate Gold Rush to Patent Your Genes’ perpetuates popular misperceptions surrounding gene patents (Holman's Biotech IP Blog) Australian pharmaceutical patent term extension for patches and implants: N V Organon; LTS Lohmann Therapie-Systeme AG and Schwarz Pharma Limited (Patent Baristas) China: Obama Administration and compulsory licensing in China (China Hearsay) China: Forty-two of Simcere’s generic drugs enter China’s Essential Drug List… [read post]
20 Jun 2009, 3:58 pm
Devon Canada Corporation recently discussed the availability of a summary judgment motion in a wrongful dismissal case. [read post]
27 May 2009, 5:27 am
(Patent Office’s rejection of Glivec’s second variant) (Spicy IP) (Spicy IP) Sweden: Anti-counterfeit barcode technology trialled in Sweden (Managing Intellectual Property) US: ACLU, PUBPAT and others file lawsuit challenging constitutionality of patents on human genes associated with breast and ovarian cancer: Association for Molecular Pathology et al v USPTO et al (Inventive Step) (Holman's Biotech IP Blog) US: Biotech sector highly critical of Commission’s… [read post]
17 Apr 2009, 10:46 am
Unfortunately, another trademark application for Octomom had already been filed by Super Happy Fun Fun, a Texas-based corporation, which submitted its application March 12th, to use the name for computer game software, toys and action figures and wireless and mobile entertainment. [read post]
14 Apr 2009, 2:04 am
Apotex had earlier made a corporate commitment to export medicines to countries in need. [read post]
22 Jan 2009, 2:06 am
As we reported yesterday, the California Supreme Court denied the petitions for review in Wyeth v. [read post]
15 Dec 2008, 2:00 pm
Then at trial in January 2007 before New York federal district court judge Sidney Stein, Apotex was found to have infringed the Plavix patent. [read post]
12 Sep 2008, 2:33 pm
: (IPRoo), Review of National Innovation System – Key points for corporate counsel: (Mallesons Stephen Jaques), Review of National Innovation System recommends creative commons: (creativecommons.org), Review of Innovation System released: (IP Menu News), What [right]’s in a [business] name: Westpac Banking Corporation v McMillan & Melbas On The Park Pty Ltd (formerly Credit Systems Australia Pty Ltd): (Australian Trade Marks Law Blog), Senator Kim Carr… [read post]
29 Aug 2008, 1:25 pm
Here is IP Think Tank’s weekly selection of top intellectual property news breaking in the blogosphere and internet. [read post]
23 Aug 2008, 1:23 am
You can separately subscribe to the IP Thinktank Global week in Review at the Subscribe page: [duncanbucknell.com]   Highlights this week included: DRM for streaming music dies a quiet death: (Electronic Frontier Foundation), (Techdirt) CAFC decides Apotex and Impax infringed AstraZeneca’s Prilosec patents: (Law360), (Patent Prospector), (Patent Docs), (GenericsWeb), CAFC upholds lower court’s decision finding USPTO was within its rights to subject a Cooper… [read post]
18 Jul 2008, 8:34 am
: (Patent Circle), Tanzania to conduct study on impact of counterfeit medicines: (Afro-IP), US: New rules on generic biological medicines under US Congressional debate: (Intellectual Property Watch), Pharma & Biotech - Products Acular (Ketorolac) – US: CAFC rules against Apotex reverse doctrine of equivalents: Roche Palo Alto & Allergan, Inc v Apotex: (Patent Circle), Carbatrol (Carbamazapine) – US: Federal judge allows Corepharma to seek DJ… [read post]
11 Jul 2008, 4:30 am
You can separately subscribe to the IP Thinktank Global week in Review at the Subscribe page: [duncanbucknell.com]   Highlights this week included: ACTA continues to be discussed and debated: (Michael Geist), (Intellectual Property Watch), (Public Knowledge),  (Techdirt), (Managing Intellectual Property), (Public Knowledge), (Public Knowledge), (Public Knowledge), Apotex challenge to Acular LS patent barred by res judicata: Roche Palo Alto & Allergan v… [read post]
30 May 2008, 9:09 am
– Brdo: (IPR-Helpdesk), 5-6 June: USFDA public meeting on evaluation of product trade names: (FDA Law Blog), 5-7 June: European research and innovation exhibition – Paris: (IPR-Helpdesk), 9-12 June: (US) Strategies for management of IP – Chicago: (IPR-Helpdesk), 11 June: US PLI ‘Advanced patent licensing 2008: What you need to know before licensing your patent’ – San Francisco: (Patent Docs), 11 June: MARQUES ‘First meeting with… [read post]
16 May 2008, 8:03 am
: (GenericsWeb), Europe: New EBA referral T 1319/04 regarding patentability of known medicament for new treatment of same illness: (IPKat), Europe: Patentability of biotechnology in Europe: (IAM), Europe: New EPO Enlarged Board case referrals: T1319/04 Dosage Regimen, T1242/06 Essential Biological Process: (Hal Wegner), Thailand: Compulsory licensing: Affordable health for Thailand thanks to Matrix Labs: (Spicy IP), Thailand: European Parliament set to reprimand Mandelson for… [read post]
2 May 2008, 7:00 am
: Lupin v Abbott Labs: (FDA Law Blog), Plavix (Clopidogrel) – US: Apotex sues FDA to recover 180-day exclusivity on generic Plavix: (Orange Book Blog), Plavix (Clopidogrel) – US: Former Bristol-Myers Squibb executive charged over lying about Plavix deal struck with rival Apotex: (Managing Intellectual Property), Risperdal (Resperidone) – US: Apotex files motion to intervene in relisting of Risperdal patent case; Teva quickly files… [read post]
28 Apr 2008, 11:00 am
: (Patent Docs), US: Supreme Court declines to hear final Nucleonics’ appeal in gene-silencing patent dispute with Benitec Australia: (IP Law360), (Therapeutics Daily), US: 505(b)(2) drug approvals rock - Interaction of patents and exclusivity of drugs approved by FDA under section 505(b)(2): (Patent Baristas), US: StemCells’ patents survive reexam – StemCells and Neuralstem differ on extent of changes: (Patent Docs), US: StemCells announces issuance of… [read post]
14 Apr 2008, 11:51 am
Apotex Inc., No. 06-3107 In state-law tort actions brought against drug manufacturers of antidepressants known as selective serotonin reuptake inhibitors ("SRRIs") based on a theory that the drugs' labeling failed to warn the risk of increased suicidal tendencies, the circuit court finds that the underlying failure-to-warn claims under state law conflicted with, and were thus preempted by FDA's regulatory actions pursuant to its authority under the Federal Food, Drug,… [read post]
14 Mar 2008, 6:07 am
While we put the Rezulin decision in the same line of authority, it lacks a clear holding that expert testimony about the meaning or violation of FDA regulations is inadmissible as a legal conclusion.An aside: Rezulin and some of the other cases also dealt with (and correctly excluded) supposed expert testimony about corporate intent. [read post]